MedTech Terms
    The authoritative reference
    All terms

    Managed Service / Reagent Rental

    Multi-year contract where instrument cost is bundled into per-test pricing.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Managed service or reagent-rental contracts bundle the capital cost of an instrument into a fixed per-test or per-procedure price across a multi-year term, eliminating customer CapEx and locking in consumables share.
    What the regulation says
    Managed service and reagent rental agreements are primarily commercial constructs. Regulatory bodies like the FDA or those governing EU MDR focus on the safety and performance of the medical devices involved, not directly on the financial arrangements. However, the service aspect implies responsibilities for device maintenance, servicing, and potentially software updates, which are covered under quality system regulations (e.g., 21 CFR 820.200 for servicing, ISO 13485:2016 clause 7.5.4 for service activities) to ensure continued compliance and patient safety.

    What this means in practice

    Standard in IVD, increasingly common in imaging AI and surgical capital. Revenue recognition (ASC 842 lease vs service) requires careful structuring.

    Examples

    • A hospital enters into a managed service agreement for a new AI-powered diagnostic imaging system, where the vendor maintains the software, performs updates, and ensures data security.
    • A clinical laboratory utilizes a reagent rental agreement for an IVD analyzer, with the vendor providing the instrument and reagents, while also handling routine maintenance and calibration as part of the per-test fee.
    • A surgical center signs a managed service contract for robotic surgery equipment, where the manufacturer provides the robot, specialized instruments, and ongoing technical support and preventive maintenance.
    Common pitfalls
    • •Confusing the commercial contract with regulatory obligations for device servicing and maintenance.
    • •Failing to establish clear responsibilities for software updates and cybersecurity patching in managed service agreements.
    • •Assuming that the financial arrangement absolves the legal manufacturer of post-market surveillance duties.
    • •Neglecting to consider the impact of service level agreements on device uptime and regulatory reporting requirements.
    • •Improperly classifying the service under financial accounting standards (e.g., ASC 842 if a lease rather than a service) can have audit and compliance implications.

    Frequently asked questions

    No, a managed service agreement does not alter the legal manufacturer's core responsibilities for ensuring the safety, efficacy, and quality of their medical device throughout its lifecycle, as stipulated by regulations like the EU MDR Annex I or FDA's 21 CFR Part 820.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    FASB·1AdvaMed·1AHRMM·1
    1. 1
      ASC 842 overview
      Verified
      FASBfasb.org
    2. 2
      AdvaMed Code of Ethics
      Verified
      AdvaMedadvamed.org
    3. 3
      AHRMM - Healthcare Supply Chain
      Verified
      AHRMMahrmm.org

    Inline markers like [1] jump to the matching reference above.